Quartz Partners LLC lifted its holdings in Encompass Health Co. (NYSE:EHC – Free Report) by 2.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 16,354 shares of the company’s stock after purchasing an additional 442 shares during the period. Encompass Health comprises 0.9% of Quartz Partners LLC’s holdings, making the stock its 28th biggest position. Quartz Partners LLC’s holdings in Encompass Health were worth $1,510,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Creative Planning increased its holdings in shares of Encompass Health by 4.1% in the 3rd quarter. Creative Planning now owns 19,086 shares of the company’s stock valued at $1,844,000 after acquiring an additional 743 shares during the period. Raymond James & Associates boosted its position in Encompass Health by 19.2% during the third quarter. Raymond James & Associates now owns 160,545 shares of the company’s stock valued at $15,515,000 after purchasing an additional 25,907 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new position in Encompass Health in the third quarter valued at about $203,000. International Assets Investment Management LLC bought a new position in Encompass Health in the third quarter worth about $4,241,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Encompass Health by 1.5% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 13,151 shares of the company’s stock worth $1,271,000 after purchasing an additional 199 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several brokerages recently weighed in on EHC. KeyCorp boosted their target price on Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. StockNews.com upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, February 15th. William Blair restated an “outperform” rating on shares of Encompass Health in a research note on Friday, February 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $110.00 price objective on shares of Encompass Health in a research note on Tuesday, February 11th. Finally, Truist Financial reissued a “buy” rating and issued a $116.00 target price (up from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. Ten analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $107.67.
Encompass Health Price Performance
Shares of EHC opened at $97.42 on Monday. The business’s 50-day moving average is $95.98 and its two-hundred day moving average is $95.96. The company has a market capitalization of $9.81 billion, a P/E ratio of 21.84, a P/E/G ratio of 2.31 and a beta of 0.90. Encompass Health Co. has a fifty-two week low of $73.68 and a fifty-two week high of $104.55. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05.
Encompass Health (NYSE:EHC – Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. Research analysts predict that Encompass Health Co. will post 4.8 earnings per share for the current year.
Encompass Health Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, April 17th. Investors of record on Tuesday, April 1st will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date of this dividend is Tuesday, April 1st. Encompass Health’s dividend payout ratio is presently 15.25%.
Insider Buying and Selling
In other news, CAO Andrew L. Price sold 5,042 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the transaction, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. The trade was a 6.79 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.10% of the stock is currently owned by insiders.
About Encompass Health
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Recommended Stories
- Five stocks we like better than Encompass Health
- Most active stocks: Dollar volume vs share volume
- 5 S&P 500 Dividend Stocks Set to Reward Investors
- The Risks of Owning Bonds
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- What Are the U.K. Market Holidays? How to Invest and Trade
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.